glp-1 drugs for parkinson's disease does not slow progression in phase 3 study GLP-1 Receptor Agonists: A New

A.LunardiG.DoimoM.TrevissonE.SalviatiL

Links Research in The Lancet Professor Thomas Foltynie's academic profile UCL Queen Square Institute of Neurology UCL Brain Sciences Image Credit: CIPhotos on iStock Media contact Poppy Tombs E: p.tombs [at] ucl.ac.uk

**Not all clinics have all therapies available

3a), and renders the synthesis of cysteine dependent on the activity of one-carbon metabolism (methionine and folate cycles)

The episode explores the science, clinical applications, and real-world considerations surrounding todays most discussed peptide therapies

The popular class of anti-ulcer drugs known as the H-2 receptor antagonists [Zantac, Tagamet, Pepcid, etc.] also depletes folic acid